- Email: [email protected]
Continuing Medical Education Exams 1-4: April 2006
GASTROENTEROLOGY 2006;130:1347–1349
CME ACTIVITIES Continuing Medical Education Exams 1-4: April 2006 Eugene Chang, MD, and Laura Harrell, MD, Editors, CME Section
CME Credits: The American Gastroenterological Association Institute (AGAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AGAI designates these educational activities for a maximum of 1.0 AMA PRA Category 1 Credit(s).™ Physicians should only claim credit commensurate with the extent of their participation in the activities.
Faculty Disclosure: In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGAI implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activities to learners.
Instructions: Category 1 credit can be earned by reading the relevant articles and taking these CME examinations online at http:// www.gastrojournal.org/content/cme.
Objectives: Upon completion of these activities, participants should be able to demonstrate an increase in or affirmation of their knowledge of clinical medicine and evaluate the appropriateness of the clinical information as it applies to the provision of patient care.
Exam 1: Thirty-Year Analysis of a Colonoscopic Surveillance Programme for Neoplasia in Ulcerative Colitis Rutter MD, et al, Authors Test ID No.: gast0014
Contact hours: 1.0
Expiration Date: April 30, 2007
Question 1: Over 50% of colorectal cancers diagnosed in this study were considered interval cancers (cancers diagnosed after a negative colonoscopy or advanced cancers diagnosed at surveillance colonoscopy). According to the authors, it may be possible to reduce the incidence of interval cancers by intensifying surveillance in all of the following patients with ulcerative colitis except:
a. b. c. d.
Patients Patients Patients Patients
with primary sclerosing cholangitis on immunomodulatory therapy with a family history of colon cancer with more severe inflammation
CME ACTIVITIES Continuing Medical Education Exams 1-4: April 2006 Eugene Chang, MD, and Laura Harrell, MD, Editors, CME Section
CME Credits: The American Gastroenterological Association Institute (AGAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AGAI designates these educational activities for a maximum of 1.0 AMA PRA Category 1 Credit(s).™ Physicians should only claim credit commensurate with the extent of their participation in the activities.
Faculty Disclosure: In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGAI implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activities to learners.
Instructions: Category 1 credit can be earned by reading the relevant articles and taking these CME examinations online at http:// www.gastrojournal.org/content/cme.
Objectives: Upon completion of these activities, participants should be able to demonstrate an increase in or affirmation of their knowledge of clinical medicine and evaluate the appropriateness of the clinical information as it applies to the provision of patient care.
Exam 1: Thirty-Year Analysis of a Colonoscopic Surveillance Programme for Neoplasia in Ulcerative Colitis Rutter MD, et al, Authors Test ID No.: gast0014
Contact hours: 1.0
Expiration Date: April 30, 2007
Question 1: Over 50% of colorectal cancers diagnosed in this study were considered interval cancers (cancers diagnosed after a negative colonoscopy or advanced cancers diagnosed at surveillance colonoscopy). According to the authors, it may be possible to reduce the incidence of interval cancers by intensifying surveillance in all of the following patients with ulcerative colitis except:
a. b. c. d.
Patients Patients Patients Patients
with primary sclerosing cholangitis on immunomodulatory therapy with a family history of colon cancer with more severe inflammation